All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
A year after agreeing to a $10 million up-front, $15 million milestones deal with Biovail SRL to develop Ampakine compounds for respiratory depression treatments, Cortex Pharmaceuticals Inc. is getting back all of the Ampakine assets and intellectual property it sold. (See BioWorld Today, March 29, 2010.)